Cutia Therapeutics (02487) Announces Increase in Issued Shares Under Pre-IPO Equity Incentive Plan

Bulletin Express

Nov 04

Cutia Therapeutics (02487) disclosed a Next Day Disclosure Return dated 03 November 2025, reporting an increase in the total number of its issued ordinary shares. The move resulted from the exercise of restricted share units and share options under the company’s Pre-IPO Equity Incentive Plan.

According to the announcement, the number of issued ordinary shares (excluding treasury shares) rose from 348,370,511 to 363,368,277, a total increase of 14,997,766. The company’s treasury share balance of 1,362,600 remained unchanged, bringing the aggregate number of issued shares to 364,730,877 as of 03 November 2025.

The company indicated that the new shares were issued at various exercise prices, including USD 0.00002, USD 0.06, and USD 0.396, depending on the terms of the underlying awards or options. All issuances were duly authorized by the board of directors and complied with applicable listing rules and legal requirements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1102695063"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1102695063\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1102695063?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 02:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1102695063","market":"us","top_or_hot":-1,"title":"Cutia Therapeutics (02487) Announces Increase in Issued Shares Under Pre-IPO Equity Incentive Plan","media":"Bulletin Express","content":"<p>Cutia Therapeutics (02487) disclosed a Next Day Disclosure Return dated 03 November 2025, reporting an increase in the total number of its issued ordinary shares. The move resulted from the exercise of restricted share units and share options under the company’s Pre-IPO Equity Incentive Plan.</p>\n<p>According to the announcement, the number of issued ordinary shares (excluding treasury shares) rose from 348,370,511 to 363,368,277, a total increase of 14,997,766. The company’s treasury share balance of 1,362,600 remained unchanged, bringing the aggregate number of issued shares to 364,730,877 as of 03 November 2025.</p>\n<p>The company indicated that the new shares were issued at various exercise prices, including USD 0.00002, USD 0.06, and USD 0.396, depending on the terms of the underlying awards or options. All issuances were duly authorized by the board of directors and complied with applicable listing rules and legal requirements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cutia Therapeutics (02487) Announces Increase in Issued Shares Under Pre-IPO Equity Incentive Plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCutia Therapeutics (02487) Announces Increase in Issued Shares Under Pre-IPO Equity Incentive Plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-11-04 02:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Cutia Therapeutics (02487) disclosed a Next Day Disclosure Return dated 03 November 2025, reporting an increase in the total number of its issued ordinary shares. The move resulted from the exercise of restricted share units and share options under the company’s Pre-IPO Equity Incentive Plan.</p>\n<p>According to the announcement, the number of issued ordinary shares (excluding treasury shares) rose from 348,370,511 to 363,368,277, a total increase of 14,997,766. The company’s treasury share balance of 1,362,600 remained unchanged, bringing the aggregate number of issued shares to 364,730,877 as of 03 November 2025.</p>\n<p>The company indicated that the new shares were issued at various exercise prices, including USD 0.00002, USD 0.06, and USD 0.396, depending on the terms of the underlying awards or options. All issuances were duly authorized by the board of directors and complied with applicable listing rules and legal requirements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02487","symbol_name":"科笛-B","start_time":0,"source_url":"","article_id":"1102695063","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1102695063","pubTimestamp":1762193327,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Cutia Therapeutics (02487) disclosed a Next Day Disclosure Return dated 03 November 2025, reporting an increase in the total number of its issued ordinary shares. The move resulted from the exercise...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02487":"科笛-B"},"translate_title":"Cutia Therapeutics(02487)公布根据首次公开发售前股权激励计划增加已发行股份","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02487":1},"content_text":"Cutia Therapeutics (02487) disclosed a Next Day Disclosure Return dated 03 November 2025, reporting an increase in the total number of its issued ordinary shares. The move resulted from the exercise of restricted share units and share options under the company’s Pre-IPO Equity Incentive Plan.\nAccording to the announcement, the number of issued ordinary shares (excluding treasury shares) rose from 348,370,511 to 363,368,277, a total increase of 14,997,766. The company’s treasury share balance of 1,362,600 remained unchanged, bringing the aggregate number of issued shares to 364,730,877 as of 03 November 2025.\nThe company indicated that the new shares were issued at various exercise prices, including USD 0.00002, USD 0.06, and USD 0.396, depending on the terms of the underlying awards or options. All issuances were duly authorized by the board of directors and complied with applicable listing rules and legal requirements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}